Articles Tagged With:
-
Emerging Treatment for Refractory Vasodilatory Shock
Shock is a common cause for intensive care unit admission, necessitating rapid treatment of the underlying cause while supporting patients with fluids and vasopressor agents. Typical vasopressor agents include adrenergic agonists and vasopressin. When shock persists despite these interventions, this is labeled refractory shock.
-
Postpartum Depression Medication Headed to Market
FDA approves first oral solution.
-
Alabama Sees Surge in Congenital Syphilis Cases and Issues Health Alert
A decade ago, Alabama saw only a few annual cases of congenital syphilis. But now the cases are spiking to record levels, including 42 cases in 2022, and possibly even more in 2023. This alarming trend caused the Alabama Department of Public Health to issue a health alert network message to providers and the public on July 18.
-
Clinicians Appear to Under-Screen, Under-Treat Patients with STIs
Insurance claims data from tens of millions of outpatient cases of patients seeking treatment for lower genitourinary tract symptoms revealed testing for sexually transmitted infections occurred in only 17.6% of all episodes.
-
STI Epidemic Continues to Escalate in United States, CDC Data Show
Syphilis rates surged in 2021, increasing by nearly one-third, and gonorrhea rates and chlamydia rates increased by close to 4%, according to the latest data on sexually transmitted infections.
-
Pregnancy with IUDs in Place: What Is the Risk of Complications?
In this retrospective cohort study, 233 individuals who conceived with a copper intrauterine device (IUD) in place were followed. There were 44 ectopic pregnancies, 31 non-viable intrauterine pregnancies, and 158 viable intrauterine pregnancies. Of the viable pregnancies, 137 patients continued the pregnancy and, of these, 54 had the IUD removed. Those who underwent IUD removal had a lower rate of pregnancy loss (33%) compared to those who retained the IUD (61.4%).
-
Does Treatment of Gestational Diabetes Before 20 Weeks of Gestation Improve Pregnancy Outcomes?
Therapy for gestational diabetes diagnosed before 20 weeks of pregnancy was associated with a slightly decreased frequency of a composite of unfavorable neonatal outcomes compared to deferred treatment or no therapy. No significant changes were demonstrated for pregnancy-related hypertension or neonatal lean body mass between the two groups.
-
Risk-Reducing Surgery and Quality of Life for Patients with Breast and Ovarian Cancer
Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) for patients at high risk of breast and ovarian cancer led to decreased cancer-related distress, unaffected health-related quality of life, poorer body image after RRM, and decreased sexual function and increased menopause symptoms after RRSO.
-
Patients Desire Telemedicine for Abortion Care
New research confirms previous studies in demonstrating the safety and efficacy of medication abortion pills. Studies also show there is strong desire for this option among people seeking an end to their pregnancy.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.